Literature DB >> 25561804

Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.

Asuka Nakarai1, Jun Kato1, Sakiko Hiraoka1, Toshihiro Inokuchi1, Daisuke Takei1, Yuki Moritou1, Mitsuhiro Akita1, Sakuma Takahashi1, Keisuke Hori1, Keita Harada1, Hiroyuki Okada1, Kazuhide Yamamoto1.   

Abstract

AIM: To determine the difference in clinical outcome between ulcerative colitis (UC) patients with Mayo endoscopic subscore (MES) 0 and those with MES 1.
METHODS: UC patients with sustained clinical remission of 6 mo or more at the time of colonoscopy were examined for clinical outcomes and the hazard ratios of clinical relapse according to MES. Parameters, including blood tests, to identify predictive factors for MES 0 and slight endoscopic recurrence in clinically stable patients were assessed. Moreover, a receiver operating characteristic curve was generated, and the area under the curve was calculated to indicate the utility of the parameters for the division between complete and partial mucosal healing. All P values were two-sided and considered significant when less than 0.05.
RESULTS: A total of 183 patients with clinical remission were examined. Patients with MES 0 (complete mucosal healing: n = 80, 44%) were much less likely to relapse than those with MES 1 (partial mucosal healing: n = 89, 48%) (P < 0.0001, log-rank test), and the hazard ratio of risk of relapse in patients with MES 1 vs MES 0 was 8.17 (95%CI: 4.19-17.96, P < 0.0001). The platelet count (PLT) < 26 × 10(4)/μL was an independent predictive factor for complete mucosal healing (OR = 4.1, 95%CI: 2.15-7.99). Among patients with MES 0 at the initial colonoscopy, patients of whom colonoscopy findings shifted to MES 1 showed significant increases in PLT compared to those who maintained MES 0 (3.8 × 10(4)/μL vs -0.6 × 10(4)/μL, P < 0.0001).
CONCLUSION: The relapse rate differed greatly between patients with complete and partial mucosal healing. A shift from complete to partial healing in clinically stable UC patients can be predicted by monitoring PLT.

Entities:  

Keywords:  Mayo endoscopic subscore; Mucosal healing; Platelet count; Ulcerative colitis

Mesh:

Year:  2014        PMID: 25561804      PMCID: PMC4277974          DOI: 10.3748/wjg.v20.i48.18367

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Reticulated platelet levels in patients with ulcerative colitis.

Authors:  Hasan Kayahan; Mesut Akarsu; Mehmet Ali Ozcan; Serdal Demir; Halil Ates; Belkis Unsal; Hale Akpinar
Journal:  Int J Colorectal Dis       Date:  2007-06-05       Impact factor: 2.571

Review 2.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

3.  Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

Authors:  C D Garlichs; S Eskafi; D Raaz; A Schmidt; J Ludwig; M Herrmann; L Klinghammer; W G Daniel; A Schmeisser
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

4.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

Review 5.  Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Authors:  Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12-04       Impact factor: 11.382

6.  The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease.

Authors:  T Colonna; B I Korelitz
Journal:  Am J Gastroenterol       Date:  1994-03       Impact factor: 10.864

7.  Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

8.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

9.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

10.  Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis.

Authors:  Kaoru Yokoyama; Kiyonori Kobayashi; Miyuki Mukae; Miwa Sada; Wasaburo Koizumi
Journal:  Gastroenterol Res Pract       Date:  2013-05-09       Impact factor: 2.260

View more
  20 in total

1.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 2.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

3.  Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.

Authors:  Shiho Takashima; Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada; Takehiro Tanaka; Kazuhide Yamamoto
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

Review 4.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

5.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

6.  Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

Authors:  Ji Young Chang; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae-Il Kim; Won-Ho Kim
Journal:  Dig Dis Sci       Date:  2018-07-09       Impact factor: 3.199

7.  Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.

Authors:  Parambir S Dulai; Siddharth Singh; Vipul Jairath; Christopher Ma; Neeraj Narula; Niels Vande Casteele; Laurent Peyrin-Biroulet; Severine Vermeire; Geert D'Haens; Brian G Feagan; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2019-11-22       Impact factor: 8.171

8.  Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.

Authors:  Makoto Naganuma; Nobuo Aoyama; Yasuo Suzuki; Haruo Nishino; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2015-11-16       Impact factor: 9.071

Review 9.  Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?

Authors:  Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Shiho Takashima; Toshihiro Inokuchi; Masao Ichinose
Journal:  Intest Res       Date:  2016-01-25

10.  Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.

Authors:  Daniël R Hoekman; Kay Diederen; Bart G P Koot; Merit M Tabbers; Angelika Kindermann; Marc A Benninga
Journal:  Eur J Pediatr       Date:  2016-08-29       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.